News und Analysen
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2023 (IFRS)
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2023 (IFRS)
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2023 (IFRS)
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its third quarter 2023 financial results after the market closes
ICON Reports Third Quarter 2023 Results
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the third quarter ended September 30, 2023.
CEO, Dr
Simulations Plus Reports Fourth Quarter and Fiscal 2023 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical drug discovery and development, today reported financial results for its
LivaNova to Present at the Stifel and Wolfe Healthcare Conferences
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova, will present a general business
EQS-News: Abivax announces Closing of its Initial Public Offering on the Nasdaq Global Market
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Society of Gene & Cell Therapy (ESGCT) has accepted six Sangamo abstracts for presentation
OSE Immunotherapeutics Announces First Clinical Results for BI 770371, a Novel Anti-SIRPα Monoclonal Antibody
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that first Phase 1 results for BI 770371, a novel anti-SIRPα monoclonal antibody evaluated in advanced
Agilent to Announce Fourth-Quarter Fiscal Year 2023 Financial Results Nov. 20
Agilent Technologies Inc. (NYSE: A) will release financial results for the fourth quarter of fiscal year 2023 after the stock market closes on Monday, Nov. 20. In addition, the company will host a
EQS-News: Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for Clinical Trials
EQS-News: Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for Clinical Trials
FDA Approves PENBRAYA™, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved PENBRAYA™ (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent
FDA Approves PENBRAYA™, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved PENBRAYA™ (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent
EQS-News: Abivax announces trading resumption of its ordinary shares on Euronext Paris
EQS-News: Eckert & Ziegler and Supervisory Board Decide on Investment Priorities for 2024: Focus on Core Competencies and Split-Off of Pentixapharm AG
EQS-News: Eckert & Ziegler and Supervisory Board Decide on Investment Priorities for 2024: Focus on Core Competencies and Split-Off of Pentixapharm AG
EQS-Adhoc: Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets
EQS-Adhoc: Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets
EQS-News: Abivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market
EQS-News: Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, November 2, 2023, following the release of its third
Agilent’s Net-Zero Emissions Targets Approved by the Science Based Targets Initiative
Agilent Technologies Inc. (NYSE: A) today announced the company’s near and long-term targets for reaching net-zero greenhouse gas emissions have been approved by the Science Based Targets
GeNeuro and Verily Collaborate to Advance Long-COVID Research
GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, announced a collaboration with Verily, an